Table 2.

Reported Drugs under Clinical Trials with Known Inhibitory Activity of TRK Kinases

NCT identifier	phase	therapeutic agent	indication	status	patient selection	estimated completion
NCT03213704	II	larotrectinib (8)	pediatric cancers	recruiting	NTRK gene fusions	09/2024
NCT02637687	II	larotrectinib (8)	CNS cancers	recruiting		06/2019
NCT02576431	II	larotrectinib (8)	NTRK+ solid tumors	recruiting	NTRK gene fusions	04/2018
NCT02122913	I	larotrectinib (8)	solid tumors	recruiting	NTRK gene fusions	02/2017
NCT03215511	I/II	LOXO-195 (9)	TRK resistant tumors	recruiting	TRK-resistant lesions	08/2019
NCT02568267	II	entrectinib (4–3)	solid tumors	recruiting	NTRK, ROS1, or ALK gene rearrangements	10/2019
NCT02097810	I	entrectinib (4–3)	advanced/metastatic cancer	active	NTRK, ROS1, or ALK molecular alterations	06/2019
NCT02650401	I	entrectinib (4–3)	pediatric and CNS cancers	recruiting	with or without NTRK, ROS1, or ALK gene fusions	08/2018
NCT01639508	II	cabozantinib (23)	advanced NSCLC	recruiting	RET, ROS1, or NTRK fusions or increased MET or AXL activity	07/2019
NCT02048488	I/IIa	belizatinib (5–3)	solid tumors and lymphomas	unknown		09/2016a
NCT02279433	I	DS-6051b	advanced solid tumors	active	NTRK or ROS1 gene rearrangements	11/2019
NCT02675491	I	DS-6051b	advanced solid tumors	active	NTRK or ROS1 gene rearrangements	09/2018
NCT02219711	I	sitravatinib (24)	advanced cancers	recruiting	MET, NTRK, or DDR2 mutations, MET or KIT/PDGFRA/VEGFR2 gene amplification, MET, RET, AXL, NTRK1, or NTRK3 gene rearrangements, or CBL gene function loss mutations	12/2018
NCT01804530	I	PLX7486	advanced solid tumors	terminated	NTRK point or fusion mutations	01/2018b
NCT02228811	I	altiratinib (25)	advanced solid tumors	terminated	NTRK or MET gene alterations	11/2017b

^aStudy has passed its completion date and status has not been verified in more than two years.

^bActual primary completion date.